文献速递痛风与晶体性关节病

萘普生与低剂量秋水仙碱治疗痛风急性发作的开放标签随机实用性试验(CONTACT)

Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care.
PubMed 文献 · Ann Rheum Dis · 2019-10-30

CONTACT 试验在基层医疗中将 399 例痛风急性发作成人随机分配至萘普生组或低剂量秋水仙碱组,比较 7 天内疼痛改善与安全性。结果显示两组平均疼痛变化无显著差异,但秋水仙碱组腹泻和头痛更常见,萘普生组便秘更常见,支持在无禁忌时萘普生作为基层一线治疗。

要点

  • 萘普生与低剂量秋水仙碱在 7 天内平均疼痛变化无显著差异。
  • 秋水仙碱组腹泻和头痛发生率高于萘普生组。
  • 无禁忌时支持萘普生作为基层痛风急性发作一线治疗。

核心结论

  • 萘普生与低剂量秋水仙碱治疗痛风急性发作在 7 天内疼痛强度变化无差异,萘普生副作用更少。

研究设计与样本

  • 多中心开放标签随机实用性试验,从 100 家全科诊所招募 399 例痛风急性发作成人,萘普生组 200 例、秋水仙碱组 199 例。
  • 萘普生 750 mg 即刻后 250 mg 每 8 小时共 7 天;低剂量秋水仙碱 500 mcg 每日三次共 4 天。
  • 主要结局为过去 24 小时最痛强度(0-10 数字评定量表)自基线的变化,前 7 天每日测量,按意向性分析比较第 1-7 天平均变化。

主要发现

  • 第 1-7 天平均疼痛变化评分组间无显著差异(秋水仙碱 vs 萘普生:平均差 -0.18;95%CI -0.53 至 0.17;p=0.32)。
  • 第 1-7 天,秋水仙碱组腹泻(45.9% vs 20.0%;OR 3.31;95%CI 2.01 至 5.44)和头痛(20.5% vs 10.7%;OR 1.92;95%CI 1.03 至 3.55)较萘普生组更常见。
  • 第 1-7 天,秋水仙碱组便秘较萘普生组更少见(4.8% vs 19.3%;OR 0.24;95%CI 0.11 至 0.54)。

临床怎么用

  • 在无禁忌证的情况下,基层医疗中痛风急性发作可优先选用萘普生。
  • 选用低剂量秋水仙碱时需注意腹泻和头痛风险更高。

局限性

  • 开放标签设计,未设盲。
  • 349 例(87.5%)完成第 7 天主要结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the effectiveness and safety of naproxen and low-dose colchicine for treating gout flares in primary care. METHODS: This was a multicentre open-label randomised trial. Adults with a gout flare recruited from 100 general practices were randomised equally to naproxen 750 mg immediately then 250 mg every 8 hours for 7 days or low-dose colchicine 500 mcg three times per day for 4 days. The primary outcome was change in worst pain intensity in the last 24 hours (0-10 Numeric Rating Scale) from baseline measured daily over the first 7 days: mean change from baseline was compared between groups over days 1-7 by intention to treat. RESULTS: Between 29 January 2014 and 31 December 2015, we recruited 399 participants (naproxen n=200, colchicine n=199), of whom 349 (87.5%) completed primary outcome data at day 7. There was no significant between-group difference in average pain-change scores over days 1-7 (colchicine vs naproxen: mean difference -0.18; 95% CI -0.53 to 0.17; p=0.32). During days 1-7, diarrhoea (45.9% vs 20.0%; OR 3.31; 2.01 to 5.44) and headache (20.5% vs 10.7%; 1.92; 1.03 to 3.55) were more common in the colchicine group than the naproxen group but constipation was less common (4.8% vs 19.3%; 0.24; 0.11 to 0.54). CONCLUSION: We found no difference in pain intensity over 7 days between people with a gout flare randomised to either naproxen or low-dose colchicine. Naproxen caused fewer side effects supporting naproxen as first-line treatment for gout flares in primary care in the absence of contraindications. TRIAL REGISTRATION NUMBER: ISRCTN (69836939), clinicaltrials.gov (NCT01994226), EudraCT (2013-001354-95).

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis. 2019. PMID: 31666237. doi:10.1136/annrheumdis-2019-216154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。